NOVADIGM THERAPEUTICS
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.
NOVADIGM THERAPEUTICS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2005-01-01
Address:
Grand Forks, North Dakota, United States
Country:
United States
Website Url:
http://www.novadigm.net
Total Employee:
11+
Status:
Active
Contact:
7013357121
Email Addresses:
[email protected]
Total Funding:
64.82 M USD
Technology used in webpage:
Viewport Meta Google Analytics Mobile Non Scaleable Content AJAX Libraries API Pound Sterling Google Analytics Classic Japanese Yen
Current Advisors List
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Convertible Note - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Series B - NovaDigm Therapeutics
Domain Associates
Domain Associates investment in Series B - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Series B - NovaDigm Therapeutics
Domain Associates
Domain Associates investment in Series A - NovaDigm Therapeutics
Official Site Inspections
http://www.novadigm.net Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K
- Host name: 878699.cloudwaysapps.com
- IP address: 146.190.217.105
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NovaDigm Therapeutics"
NovaDigm Therapeutics - Crunchbase Company Profile & Funding
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in โฆSee details»
Organization | NovaDigm Therapeutics, Inc.
Organization Overview. First Clinical Trial. 2011 NCT01273922. First Marketed Drug. None First NDA Approval. None Last Known Activity ... NovaDigm Therapeutics, Inc. Active Ingredients. โฆSee details»
NovaDigm Therapeutics - Craft
NovaDigm Therapeutics is a company that develops immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease. It provides NDV-3A, a vaccine โฆSee details»
novadigm.net
Novadigm.netSee details»
Novadigm Therapeutics Company Profile 2024: โฆ
Operators of an immunotherapeutic company intended to protect people from fungal and bacterial diseases.See details»
Novadigm Therapeutics, Inc. Company Profile | Brookline, MA ...
Find company research, competitor information, contact details & financial data for Novadigm Therapeutics, Inc. of Brookline, MA. Get the latest business insights from Dun & Bradstreet.See details»
NovaDigm Therapeutics - Products, Competitors, Financials, โฆ
NovaDigm Therapeutics is a biotechnology company focused on developing immunotherapeutics and preventative vaccines for fungal and bacterial diseases. Use the CB Insights Platform to โฆSee details»
NovaDigm Therapeutics - Overview, News & Similar companies
Who is NovaDigm Therapeutics. NovaDigm is developing innovative immunotherapeutic and preventative vaccines to protect patients from fungal and bacterial diseases, which can be โฆSee details»
NovaDigm Therapeutics - Org chart - The Org
Explore NovaDigm Therapeutics' organizational chart. Discover current team members including executives, board members, and advisors.See details»
NovaDigm Therapeutics, Inc. - Drug pipelines, Patents, Clinical โฆ
Explore NovaDigm Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 6 literature, Drug:NDV-4, Recombinant protein vaccine (NDV-3) against โฆSee details»
Questionnaire for a Biotech - PMC - National Center for โฆ
Aug 1, 2013ย ยท NovaDigm is a product-focused company based on recombinant antigens from the fungal pathogen Candida albicans that were in-licensed from LA BioMed. We are currently โฆSee details»
Novadigm - Crunchbase Company Profile & Funding
Apr 5, 2004ย ยท Novadigm engages in the development, marketing, and support of software solutions that automate the configuration and change-management of digital assets. Its โฆSee details»
Your Cookie Settings
Biopharmaceutical and Biotechnology Management Consulting. Broad range of services for Biopharmaceutical, Diagostic and Industrial Biotechnology companies, from techology, โฆSee details»
Novadigm Company Profile 2024: Valuation, Investors, Acquisition ...
Information on acquisition, funding, investors, and executives for Novadigm. Use the PitchBook Platform to explore the full profile.See details»
Positive Phase 2 results of NovaDigm TX's NDV | EurekAlert!
Apr 25, 2018ย ยท NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication โฆSee details»
Full article: Questionnaire for a Biotech - Taylor & Francis Online
Nov 20, 2013ย ยท NovaDigm is a product-focused company based on recombinant antigens from the fungal pathogen Candida albicans that were in-licensed from LA BioMed. We are currently โฆSee details»
HP Agrees To Acquire Novadigm, Consera - Network Computing
Feb 5, 2004ย ยท Hewlett-Packard Co. on Wednesday said it has agreed to acquire Novadigm Inc. and closely held Consera Software, and plans to add the two companies' technology โฆSee details»
NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Candida and ...
Oct 22, 2012ย ยท The investigational vaccine, NDV-3, contains the N-terminal portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) formulated with an aluminum hydroxide โฆSee details»
Fungal Immunotherapeutic Vaccine (NDV-3A) for ... - Oxford โฆ
Apr 25, 2018ย ยท In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced โฆSee details»
NovaDigm Therapeutics, Inc. (NovaDigm Therapeutics, Inc.) - ่ฏ็ฉ โฆ
Methods This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin โฆSee details»